Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cigna’s Bradbury Talks PCSK9 Contracts And Value Versus Volume

Executive Summary

Amgen and Sanofi/Regeneron will pay deeper discounts if patients taking Repatha and Praluent don’t experience similar levels of LDL-cholesterol lowering as was seen in clinical trials.


Related Content

Express Scripts Combination With Cigna's PBM Could Reverse Deficit From Losing Anthem
The Outcomes-Based Reimbursement Experiment
US Outcomes-Based Contracts: Big Uptick In Interest, But Not Execution
Lilly Diabetes Extends Feelers Into Other Diseases
Regeneron: PCSK9s Drowning In Paperwork
Novartis To Payers: Entresto Works Or You Get A Discount
A Closer Look At The US Pricing Pushback


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts